Abstract
Background: Sofosbuvir is a direct-acting antiviral drug used to treat chronic hepatitis C infection. In 2015, Gilead Sciences, the manufacturer of sofosbuvir, warned that bradycardia could occur when sofosbuvir is administered in combination with amiodarone. Interestingly, among the reported cases of patients with sofosbuvir and amiodarone related bradycardia, some of them were also treated with propranolol.
Objective: We herein report a case of ventricular extrasystoles within three hours after the coadministration of sofosbuvir-containing regimen with propranolol. This patient had never been treated with amiodarone. After the sofosbuvir-containing regimen was stopped, ventricular extrasystoles disappeared within 24 hours. This observation suggests that the association of sofosbuvir with propranolol may have a role in the emergence of cardiac arrhythmia.
Conclusion: Patients treated with amiodarone and/or propranolol should be continuously monitored within the early hours following the initiation of sofosbuvir.
Keywords: Cardiac arrhythmia, drug interaction, extrasystole, Hepatitis C, propranolol, sofosbuvir.
Reviews on Recent Clinical Trials
Title:Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report
Volume: 12 Issue: 3
Author(s): Samir Rouabhia*, Sabah Baghazza, Hamza Sadouki, Sihem Djezzar, Rafik Bencherif, Rofia Guehimeche, Mourad Sadelaoud, Djamel Mallem and Karima Chaabna
Affiliation:
- Department of Internal Medicine, University Hospital Center Touhami Benflis, Batna 05000, Algeria and Department of Medicine, University Batna 2, Batna 05000,Algeria
Keywords: Cardiac arrhythmia, drug interaction, extrasystole, Hepatitis C, propranolol, sofosbuvir.
Abstract: Background: Sofosbuvir is a direct-acting antiviral drug used to treat chronic hepatitis C infection. In 2015, Gilead Sciences, the manufacturer of sofosbuvir, warned that bradycardia could occur when sofosbuvir is administered in combination with amiodarone. Interestingly, among the reported cases of patients with sofosbuvir and amiodarone related bradycardia, some of them were also treated with propranolol.
Objective: We herein report a case of ventricular extrasystoles within three hours after the coadministration of sofosbuvir-containing regimen with propranolol. This patient had never been treated with amiodarone. After the sofosbuvir-containing regimen was stopped, ventricular extrasystoles disappeared within 24 hours. This observation suggests that the association of sofosbuvir with propranolol may have a role in the emergence of cardiac arrhythmia.
Conclusion: Patients treated with amiodarone and/or propranolol should be continuously monitored within the early hours following the initiation of sofosbuvir.
Export Options
About this article
Cite this article as:
Rouabhia Samir *, Baghazza Sabah , Sadouki Hamza, Djezzar Sihem , Bencherif Rafik, Guehimeche Rofia , Sadelaoud Mourad, Mallem Djamel and Chaabna Karima, Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report, Reviews on Recent Clinical Trials 2017; 12 (3) . https://dx.doi.org/10.2174/1574887112666170725132044
DOI https://dx.doi.org/10.2174/1574887112666170725132044 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews Role of Sensory Neurons in Restitution and Healing of Gastric Ulcers
Current Pharmaceutical Design Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Risk Factors for Development of Heart Failure
Current Cardiology Reviews Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Regulatory Mechanism of the Gastric Hyperemic Response Following Barrier Disruption: Roles of Cyclooxygenase-1, the Prostaglandin E<sub>2</sub>/EP1 Receptor and Sensory Neurons
Current Pharmaceutical Design Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Transforming Growth Factor-β1 Gene Polymorphism and Its Serum Levels in Hashimoto’s Thyroiditis
Current Pharmaceutical Biotechnology Recent Advances in GNAS Epigenetic Research of Pseudohypoparathyroidism
Current Molecular Medicine The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Novel Approaches to the Pharmacotherapy of Obesity
Current Pharmaceutical Design The Influence of Microneedles on the Percutaneous Penetration of Selected Antihypertensive Agents: Diltiazem Hydrochloride and Perindopril Erbumine
Current Drug Delivery Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including their Transporters
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Targeting Inflammation in Cardiovascular Disease)
Medicinal Chemistry A Critical Approach of Guideline Therapeutic Recommendations for NAFLD
Current Vascular Pharmacology Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery